Loading organizations...
§ Private Profile · Leopoldshafen, Baden-Wurttemberg, Germany
Clinical-stage biotechnology company developing first-in-class peptide-based therapeutics for metastatic cancers.
Based in Eggenstein-Leopoldshafen, Germany, amcure is a clinical-stage biopharmaceutical company that develops first-in-class peptide-based therapeutics for the treatment of highly metastatic cancers and advanced solid tumors. The organization focuses on oncology research with its lead drug candidate, AMC303, which targets the CD44v6 receptor to inhibit tumor growth and prevent cancer cells from spreading to other organs. Operating with a team of fewer than 50 employees, the biotechnology firm has raised approximately €14 million across multiple financing rounds to support its clinical development programs. This total capital includes an €8 million Series A and a €6 million Series B backed by institutional investors such as LBBW Venture Capital, BioMedPartners, and KfW. The company was established in 2012 as a spin-off from the Karlsruhe Institute of Technology by founders Dr. Veronika Orian-Rousseau and Dr. Alexandra Matzke.
amcure has raised $6.4M across 1 funding round.
amcure has raised $6.4M in total across 1 funding round.
amcure has raised $6.4M across 1 funding round. Most recently, it raised $6.4M Series B in December 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 14, 2016 | $6.4M Series B | Harald Poth | Karlsruhe Institute OF Technology, KFW, MBG Mittelstndische Beteiligungsgesellschaft Baden Wrttemberg, S KAP Unternehmensbeteiligungs | Announced |
amcure has raised $6.4M in total across 1 funding round.
amcure's investors include Harald Poth, Karlsruhe Institute of Technology, KfW, MBG Mittelstndische Beteiligungsgesellschaft Baden-Wrttemberg, S-Kap Unternehmensbeteiligungs.